SHL Telemedicine (SHLTN.SW) up 7.11% to CHF1.18 on SIX 06 Jan 2026: momentum
SHLTN.SW stock jumped 7.11% to CHF 1.18 on the SIX at market close on 06 Jan 2026, making SHL Telemedicine one of today’s top gainers in Swiss healthcare. Trading volume of 78,716 shares exceeded the 50-day average, driven by short-term momentum and renewed investor focus on telemedicine device contracts. We examine why the market moved, the company’s valuation and the risk profile for investors tracking SHL Telemedicine Ltd. (SHLTN.SW). Meyka AI-powered market analysis highlights technical drivers plus a model forecast to guide short-term price expectations.
Intraday move and trading flow for SHLTN.SW stock
SHL Telemedicine (SHLTN.SW) closed at CHF 1.18 after intraday highs of CHF 1.20 on SIX on 06 Jan 2026. Volume was 78,716 versus an average volume of 20,049, signalling above-average interest.
The 1-day change metric shows a strong short-term swing (reported 7.11%), while the 50-day average price is CHF 1.07 and the 200-day average is CHF 1.53, underlining recent volatility and the gap between near-term momentum and longer-term trend.
Fundamentals and valuation snapshot
SHL Telemedicine Ltd. reports a market cap near CHF 18.03 million and shares outstanding 16,390,977. Key metrics: EPS -0.76, PE -1.45, Price/Sales 0.40, Price/Book 0.59, and current ratio 0.87, which suggests short-term liquidity pressure.
Profitability ratios show a gross margin 45.25% and negative operating margin -46.40%, reflecting R&D and monitoring costs. Debt/equity is 0.38, a moderate leverage level for a small-cap healthcare device and services firm.
Technicals, momentum indicators and Meyka AI grade
Technicals show neutral momentum: RSI 49.56, MACD flat, Bollinger bands at 1.28 / 1.06 / 0.84. Volatility measures (ATR 0.14) and a high MFI (76.19) point to active buying interest but limited trend strength (ADX 8.86).
Meyka AI rates SHLTN.SW with a score out of 100: 65.75 (Grade B), suggestion HOLD. This grade factors S&P 500 comparison, sector and industry peers, financial growth, key metrics, forecasts and analyst inputs. The grade is informational and not financial advice.
Catalysts, partnerships and near-term earnings outlook
SHL’s collaborations — including work with Mayo Clinic and Hebrew University on AI-enabled cardiac monitoring — are key growth catalysts that can lift adoption for devices like SmartHeart. These partnerships may support recurring monitoring contracts and device sales.
Upcoming earnings calendar notes show next announcements and mixed recent beats and misses; revenue estimates for recent periods are around CHF 28.56 million (quarterly estimate) and EPS estimates -0.01587 for Sept 2025. Investors should watch contract rollouts and any FDA/CE regulatory updates.
Price targets, forecast and scenario planning for SHLTN.SW stock
Meyka AI’s forecast model projects a quarterly price of CHF 1.34, implying +13.56% upside from CHF 1.18. The model’s monthly figure is CHF 1.17 (-0.85%) and a 12-month model price is CHF 1.11 (-5.97%), showing short-term upside but longer-horizon risk.
Analyst-style scenario targets for traders: conservative CHF 1.50 (+27.12%), optimistic CHF 2.30 (+94.92%), downside CHF 0.80 (-32.20%). These targets reflect valuation, thin liquidity and binary catalyst risk.
Sector context and liquidity considerations
In the Healthcare sector on SIX, average Price/Sales is 2.49; SHL’s P/S of 0.40 signals a deep discount versus sector peers. That gap can reflect smaller scale, negative margins and execution risk despite technical strengths.
Low liquidity and elevated short-term volatility require position sizing discipline; SHLTN.SW’s average volume 20,049 means exits and large buys can move price materially.
Final Thoughts
SHLTN.SW stock’s CHF 1.18 close on 06 Jan 2026 reflects a short-term rebound that traders recordable as a top gainer day. The company combines attractive device IP and high-profile research ties with constrained financial metrics: EPS -0.76, negative operating margin and current ratio 0.87, which keep structural risks in place. Meyka AI’s forecast model projects a quarterly price of CHF 1.34, an implied +13.56% upside versus today’s close, while a 12-month model price near CHF 1.11 flags possible downside over a longer horizon. For investors we frame SHL Telemedicine as a speculative small-cap exposure: potential upside if partnerships convert to contracts, balanced by earnings deficits and low liquidity. Our scenario targets range from CHF 0.80 (bear) to CHF 2.30 (bull); risk-aware traders should size positions and watch upcoming revenue/earnings updates and clinical validation milestones. This analysis uses public data and Meyka AI modelling; forecasts are model-based projections and not guarantees.
FAQs
Volume jumped to **78,716** and the share price rose to **CHF 1.18**, driven by short-term momentum and renewed interest in telemedicine partnerships and device rollouts.
Meyka AI’s model shows a quarterly target **CHF 1.34** (+13.56%) from **CHF 1.18** today, with a 12-month projection near **CHF 1.11** that signals longer-term risk.
By Price/Sales, SHL’s **0.40** compares with Healthcare sector average **2.49**, suggesting a valuation gap, but negative margins and liquidity concerns justify a discount.
Key risks include negative earnings (**EPS -0.76**), current ratio below 1 (**0.87**), thin daily liquidity and execution risk converting clinical partnerships into recurring revenue.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
